Harvard Bioscience (HBIO) Income towards Parent Company (2016 - 2025)
Harvard Bioscience (HBIO) has disclosed Income towards Parent Company for 15 consecutive years, with -$3.4 million as the latest value for Q4 2025.
- Quarterly Income towards Parent Company fell 1127.74% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$57.2 million through Dec 2025, down 375.84% year-over-year, with the annual reading at -$57.3 million for FY2025, 373.36% down from the prior year.
- Income towards Parent Company for Q4 2025 was -$3.4 million at Harvard Bioscience, down from -$1.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $2.4 million in Q2 2022, with the low at -$50.3 million in Q1 2025.
- Average Income towards Parent Company over 5 years is -$4.1 million, with a median of -$1.4 million recorded in 2023.
- Peak annual rise in Income towards Parent Company hit 693.9% in 2022, while the deepest fall reached 1902.94% in 2022.
- Over 5 years, Income towards Parent Company stood at $590000.0 in 2021, then tumbled by 382.37% to -$1.7 million in 2022, then grew by 4.56% to -$1.6 million in 2023, then surged by 120.63% to $328000.0 in 2024, then crashed by 1127.74% to -$3.4 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods came in at -$3.4 million, -$1.2 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.